REG - Belluscura PLC - Direct to Consumer Sales and Distribution Plan

BelluscuraAnnouncement

30/06/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220630:nRSd7145Qa&default-theme=true

RNS Number : 7145Q  Belluscura PLC  30 June 2022

 

Belluscura PLC

("Belluscura" or the "Company")

 

Belluscura Launches Direct to Consumer Sales and Distribution Plan

 

New Direct to Consumer and Partnership Distributor Plan expected to increase
revenue and gross profits

 

LONDON, U.K. AND PLANO, TX, U.S. (30 June 2022). Belluscura plc (AIM: BELL), a
leading medical device developer focused on lightweight and portable oxygen
enrichment technology, announces that it has commenced selling its X-PLOR
oxygen concentrators direct to consumers ("DTC") from the following website:
www.xploroxygen.com (http://www.xploroxygen.com) .

 

The Company has also started a new partnership distribution programme directed
at increasing the availability of portable oxygen concentrators to small,
local durable medical equipment providers who are experiencing considerable
delays in the wait for portable concentrators. Both initiatives are expected
to significantly expand our distribution network across the US and to increase
revenue and profits. A brochure containing information on the X-PLOR oxygen
concentrator can be found here
http://www.rns-pdf.londonstockexchange.com/rns/7145Q_1-2022-6-29.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/7145Q_1-2022-6-29.pdf) .

 

Robert Rauker, CEO of Belluscura plc, said: "Selling our products direct to
consumers allow us to generate higher revenue and increased profits over the
longer term. In addition, our new Partnership Distribution Plan is directed at
smaller distributors, further expanding our distribution network throughout
the US."

 

Adam Reynolds, Chairman of Belluscura plc, said "Both the launch of direct to
consumers sales along with making our product available to the hundreds of
smaller, local supplemental oxygen providers, creates significant
opportunities for Belluscura."

 

For further information please contact:

 

 Belluscura plc                                    www.belluscura.com (http://www.belluscura.com)
 Robert Rauker, Chief Executive Officer            via Walbrook PR
 Anthony Dyer, Chief Financial Officer

 SPARK Advisory Partners Limited (NOMAD)           Tel: +44 (0)20 3368 3550
 Neil Baldwin

 Dowgate Capital Limited (Broker)                  Tel: +44 (0)20 3903 7715
 James Serjeant / Nicholas Chambers

 Walbrook PR Ltd (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com
 Paul McManus / Sam Allen                          Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

 

 

About Belluscura plc (www.belluscura.com (http://www.belluscura.com) )

Belluscura is a UK medical device company focused on developing oxygen
enrichment technology spanning broad industries and therapies. Our innovative
oxygen technologies are designed with a global purpose: to create improved
health and economic outcomes for the patients, healthcare providers and
insurance organisations.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLMFTMTATBRT